Enspryng 120 mg, Injektionslösung zur subkutanen Anwendung
7680676170011
CH-67617
Injektionslösung zur subkutanen Anwendung
Associated product:
ENSPRYNG sol inj 120 mg/ml ser pré 1 ml
1 / 3
google
Article details
- Package size
- 1
- Selling units
- 1
- Measure
- Fertigspritze(n)
- Galenic form
- Injektionslösung zur subkutanen Anwendung
- Galenic group
- unbekannt
Official Swissmedic V2 data
Additional information from the official database
Official medical documents
Detailed composition
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
satralizumabum
|
120.0 MG | Substance | Wirkstoff (Principe actif) |
|
histidinum
|
- | Substance | HNIDK |
|
acidum asparticum
|
- | Substance | HNIDK |
|
argininum
|
- | Substance | HNIDK |
|
poloxamerum 188
|
- | Substance | HNIDK |
|
aqua ad iniectabile
|
- | Substance | HNIDK |
Reimbursement information
Public price
CHF 7164.10
Specialties list
Yes
Generic
No
Reimbursement limitation
SL addition date:
01/04/2022
Authorization holder
Roche Pharma (Schweiz) AG
4058 Basel
Authorization information
- Swissmedic authorization number
- 67617
- Drug name
- Enspryng, Injektionslösung zur subkutanen Anwendung
- Galenic form
- INLFS
- ATC Code
- L04AC19
- Authorization status
- Z
- Dispensing category
- A
- First authorization
- 13/07/2020
- Authorization expiration date
- 31/12/9999
- IT Number
- 07.15.0.
- Domain
- Human medicine
Package details
- Description (FR)
- ENSPRYNG sol inj 120 mg/ml ser pré 1 ml
- Description (DE)
- ENSPRYNG Inj Lös 120 mg/ml Fertspr 1 ml
- Market launch
- 13/07/2020
- Narcotic (BTM)
- No